血管内皮抑制素联合放化疗治疗晚期非小细胞肺癌的临床研究

doi:10.3760/cma.j.issn.1673-422X.2014.12.019

摘要/Abstract

摘要： 目的初步探讨血管内皮抑制素（ES）联合放化疗治疗晚期非小细胞肺癌（NSCLC）临床疗效及不良反应，评价其有效性及安全性。方法回顾性分析哈尔滨医科大学肿瘤医院2009年2月至2012年2月收治的ⅢB~Ⅳ期的64例NSCLC患者，分为放化疗组及ES+放化疗组。观察两组患者的近期疗效，比较两组的总有效率、中位生存时间、无进展生存时间及无瘤生存时间。结果放化疗组39例，总有效率为76.9%；ES+放化疗组25例，总有效率为84.0%（χ2=0.47, P=0.492）。放化疗组与ES+放化疗组中位生存时间、中位无进展生存时间、中位无瘤生存时间分别为11.52个月∶16.51个月（ χ2=3.74, P=0.042）、7.32个月∶10.37个月（ χ2=5.32, P=0.025）和5.21个月∶7.57个月（ χ2=4.56, P=0.035）。主要药物不良反应均为血液学毒性及消化道反应，但两组间差异无统计学意义；放疗不良反应主要表现为1~2级放射性肺损伤及放射性食管炎（其中放化疗组出现1例3级放射性肺损伤），两组间差异无统计学意义。结论ES联合放化疗治疗晚期NSCLC可获得较好的近期临床疗效且不增加放化疗不良反应。

关键词: 癌, 非小细胞肺, 放射疗法, 化学疗法, 辅助, 血管内皮抑制素

Abstract: ObjectiveTo preliminary study clinical efficacy and toxicity of endostatin (ES) combined radiotherapy and chemotherapy in advanced nonsmall cell lung cancer (NSCLC), and evaluate its effectiveness and safety. MethodsWe retrospectively reviewed 64 patients with ⅢBⅣ stage NSCLC of Harbin Medical University Cancer Hospital from February 2009 to February 2012.The patients were divided into two groups:chemoradiotherapy group, 39 patients and ES add chemoradiotherapy group, 25 patients. The shortterm effect, the total efficiency, median survival time, progressionfree survival time and diseasefree survival time were compared. ResultsThe total effective rate of chemoradiotherapy group was 76.9%, while the total effective rate of ES add chemotherapy group was 84.0%（χ2=0.47, P=0.492）. Chemoradiotherapy group, compared to ES add chemotherapy group, the median survival time, median progressionfree survival time, median diseasefree survival time were 11.52 months vs 16.51 months (χ2=3.74, P=0.042), 7.32 months vs 10.37 months (χ2=5.32, P=0.025) and 5.21 months vs 7.57 months (χ2=4.56, P=0.035)respectively. The mainly adverse drug reactions were hematologic toxicity and gastrointestinal reactions, but there were no significant differences between the two groups; radiotherapy side effects mainly showed the grade 1 to 2 radiationinduced lung injury and radiation esophagitis (chemotherapy group had one case of grade 3 radiationinduced lung injury), but also had no significant differences between the two groups. ConclusionES combined chemoradiotherapy can achieve a better shortterm clinical efficacy without increasing adverse effects of radiotherapy or chemotherapy in advanced nonsmall cell lung cancer.

Key words: Carcinoma, non-small cell lung, Radiotherapy, Chemotherapy, adjuvant, Endostatins

张磊, 曹勇. 血管内皮抑制素联合放化疗治疗晚期非小细胞肺癌的临床研究[J]. 国际肿瘤学杂志, 2014, 41(12): 941-945.

ZHANG Lei, CAO Yong. Endostatins combined radiotherapy and chemotherapy in the treatment of advanced non-small cell lung cancer[J]. Journal of International Oncology, 2014, 41(12): 941-945.

参考文献

［1］ Bayman N, Alam N, FaivreFinn C, et al. Radiotherapy for lung cancer in the elderly［J］. Lung Cancer, 2010, 68(2): 129136. ［2］ Hill EK, Dizon DS. Medical therapy of endometrial cancer: current status and promising novel treatments［J］. Drugs, 2012, 72(5): 705713. ［3］ Seppinen L, Pihlajaniemi T. The multiple functions of collagen ⅩⅧin development and disease［J］. Matrix Biol, 2011, 30(2): 8392. ［4］ Morgensztern D, Ng SH, Gao F, et al. Trends in stage distribution for patients with nonsmall cell lung cancer: a national cancer database survey［J］. J Thorac Oncol, 2010, 5(1): 2933. ［5］ Folkman J. Tumor angiogenesis: therapeutic implications［J］. N Engl Med, 1971, 285(21): 11821186. ［6］ Liu ZJ, Wang J, Wei XY, et al. Predictive value of circulating endothelial cells of efficacy of chemotherapy with Rhendostatin in nonsmall cell lung cancer［J］. Cancer Res Clin Oncol, 2012, 138(6): 927937. ［7］ Huang GC, Chen LB. Recombinant human endostatin improves antitumor efficacy of paclitaxel by normalizing tumor vasculature in Lewis lung carcinoma［J］. Cancer Res Clin Oncol, 2010, 136(8): 12011211. ［8］ Li BS, Gong HY, Huang W, et al. Phase Ⅰ study of pemetrexed,cisplatin,and concurrent radiotherapy in patients with locally advanced nonsmall cell lung cancer［J］. Am J Clin Oncol, 2012, 35(2): 115119. ［9］ Artman T, Schilling D, Gnann J, et al. Irradiationinduced regulation of plasminogen activator inhibit or type1 and vascular endothelial growth factor in six human squamous cell carcinoma lines of the head and neck［J］. Int J Radiat Oncol Biol Phys, 2010, 76(2): 574582. ［10］ Kessler T, Bayer M, Schwppe C, et al. Compounds in clinical Phase Ⅲ and beyond［J］. Recent Results Cancer Res, 2010, 180: 137163. ［11］ Jiang XD, Dai P, Wu J, et al. Inhibitory effect of radiotherapy combined with weekly recombinant human endostatin on the human pulmonary adenocarcinoma A549 xenografts in nude mice［J］. Lung Cancer, 2011, 72(2): 165171. ［12］ Carter DL, Garfield D, Hathorn J, et al. A randomized phase Ⅲ trial of combined paclitaxel, carboplatin, and radiation therapy followed by weekly paclitaxel or observation for patients with locally advanced inoperable nonsmallcell lung cancer［J］. Clin Lung Cancer, 2012, 13(3): 205213. ［13］刘婷婷, 韩波. VEGF与非小细胞肺癌放射治疗研究进展［J］. 实用肿瘤学杂志, 2012, 26(6): 564568. ［14］隋黎丽, 王欣, 管乐静. 恩度联合放化疗同步治疗非小细胞肺癌的临床观察［J］. 中国肺癌杂志, 2009, 12(6): 560561. ［15］刘金, 黄京, 全吉钟, 等. 放化疗同步联合YH16治疗局部晚期NSCLC的临床研究［J］. 中国医药导报, 2009, 6(16): 253254. ［16］陈轩, 徐向英. 图像引导放射治疗在肺癌中的临床应用［J］. 实用肿瘤学杂志, 2012, 26(1): 7174. ［17］ Grills IS, Hugo G, Kestin LL, et al. Imageguided radiotherapy via daily online conebeam CT substantially reduces margin requirements for stereotactic lung radiotherapy［J］. Int J Radiat Oncol Biol Phys, 2008, 70(4): 10451056. ［18］赵卫刚, 胡世莲, 沈干, 等. 恩度联合化疗治疗非小细胞肺癌的系统评价［J］. 中国循证医学杂志, 2011, 11(10): 11441150. ［19］ Chaves KC, Peron JP, Chammas R, et al. Endostatin gene therapy stimulates upregulation of ICAM1 in a metastatic renal cell carcinoma model［J］. Cancer Gene Ther, 2012, 19(8): 558565. ［20］ Weichselbaum RR. How does antiangiogenic therapy affect brain tumor response to radiation?［J］. Nat Clin Pract Oncol, 2005, 2(5): 232233. ［21］ Jiang XD, Dai P, Wu J, et al. Effect of recombinant human endostatin on radiosensitivity in patients with nonsmallcell lung cancer［J］. Int J Radiat Oncol Biol Phys, 2012, 83(4): 12721277. ［22］ Zhou JF, Bai CM, Wang YZ, et al. Endostar combined with chemotherapy for treatment of metastatic colorectal and gastric cancer:a pilot study［J］. Chin Med J(Engl), 2011, 124(24): 42994303.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[4]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[5]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[6]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[7]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[8]	顾芳萌, 徐晨阳, 雷大鹏. 人工智能辅助电子喉镜检查在喉癌及喉癌前病变诊治中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(5): 303-307.
[9]	张文馨, 夏泠, 彭晋, 周福祥. 甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[10]	王昆, 周中新, 臧其威. 血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[11]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇. 信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[12]	姚益新, 沈煜霖. 血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[13]	胡婷婷, 王越华. 电子鼻与线虫鼻——新型早期癌症筛查工具[J]. 国际肿瘤学杂志, 2024, 51(4): 223-226.
[14]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[15]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.